The neuroprotective effect of GLP-1RAs through GABAergic modulation not only supports its clinical potential in neurodegenerative diseases such as AD, HD, and Parkinson’s diseases (PD), but also adds to our fundamental understanding of GLP-1’s pleiotropic molecular network with a special focus on its ocular therapeutic potential. The gene discussed is GCG; the disease is Parkinson disease.